Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

886 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.
Desai J, Wagner AJ, Carrasco Garcia I, Cesari M, Gordon M, Lin CC, Papai Z, Ryan CW, Tap WD, Trent JC, Gelderblom H, Grimison P, López Pousa A, Van Tine BA, Rubinacci M, Dai D, Rajper AW, Tecson K, Wooddell M, Stacchiotti S. Desai J, et al. Among authors: gelderblom h. Cancer. 2025 Jan 1;131(1):e35634. doi: 10.1002/cncr.35634. Epub 2024 Nov 12. Cancer. 2025. PMID: 39533157 Free PMC article. Clinical Trial.
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, van der Graaf WT, Italiano A, Seddon B, Dômont J, Bompas E, Wagner AJ, Blay JY. Cassier PA, et al. Among authors: gelderblom h. Cancer. 2012 Mar 15;118(6):1649-55. doi: 10.1002/cncr.26409. Epub 2011 Aug 5. Cancer. 2012. PMID: 21823110 Free article.
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, Kapiteijn E, Gelderblom H, Nijman HW, Valentijn AR, Oostendorp J, Fathers LM, Drijfhout JW, van de Velde CJ, Kuppen PJ, van der Burg SH, Melief CJ. Zeestraten EC, et al. Among authors: gelderblom h. Int J Cancer. 2013 Apr 1;132(7):1581-91. doi: 10.1002/ijc.27819. Epub 2012 Nov 21. Int J Cancer. 2013. PMID: 22948952 Clinical Trial.
Outcome of advanced, unresectable conventional central chondrosarcoma.
van Maldegem AM, Gelderblom H, Palmerini E, Dijkstra SD, Gambarotti M, Ruggieri P, Nout RA, van de Sande MA, Ferrari C, Ferrari S, Bovée JV, Picci P. van Maldegem AM, et al. Among authors: gelderblom h. Cancer. 2014 Oct 15;120(20):3159-64. doi: 10.1002/cncr.28845. Epub 2014 Jul 3. Cancer. 2014. PMID: 24995550 Free article.
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.
Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P. Gaston CL, et al. Among authors: gelderblom h. Clin Sarcoma Res. 2016 Sep 14;6(1):15. doi: 10.1186/s13569-016-0056-0. eCollection 2016. Clin Sarcoma Res. 2016. PMID: 27651889 Free PMC article. Review.
A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
Wagner AJ, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P. Wagner AJ, et al. Among authors: gelderblom h. Ann Oncol. 2017 Mar 1;28(3):541-546. doi: 10.1093/annonc/mdw659. Ann Oncol. 2017. PMID: 28426120 Free PMC article. Clinical Trial.
Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali P, Gronchi A, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R. Rutkowski P, et al. Among authors: gelderblom h. Eur J Surg Oncol. 2018 Sep;44(9):1384-1390. doi: 10.1016/j.ejso.2018.03.020. Epub 2018 Mar 31. Eur J Surg Oncol. 2018. PMID: 29650420 Clinical Trial.
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Frezza AM, et al. Among authors: gelderblom h. JAMA Oncol. 2018 Sep 1;4(9):e180219. doi: 10.1001/jamaoncol.2018.0219. Epub 2018 Sep 13. JAMA Oncol. 2018. PMID: 29800950 Free PMC article.
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marreaud S, Kasper B, Gelderblom H, Stacchiotti S, Judson I, Dei Tos AP, Verderio P, Casali PG, Woll PJ, Gronchi A; EORTC – Soft Tissue and Bone Sarcoma Group. Pasquali S, et al. Among authors: gelderblom h. Eur J Cancer. 2019 Mar;109:51-60. doi: 10.1016/j.ejca.2018.12.009. Epub 2019 Jan 25. Eur J Cancer. 2019. PMID: 30690293 Clinical Trial.
886 results